Eliem Therapeutics Announces Plans to Explore Strategic Alternatives
SEATTLE and CAMBRIDGE, United Kingdom, July 20, 2023 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (Nasdaq:ELYM) today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities, and has made the determination to halt further development of its Kv7 program and to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value. Eliem has engaged Leerink Partners to act as a strategic advisor in the process.
Related news for (ELYM)
- eliem therapeutics announces rebranding and corporate name change to climb bio, inc.
- eliem therapeutics announces additions to its leadership team
- Eliem Therapeutics Enters $120 Million Private Placement to Acquire Tenet Medicines
- Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference